Portfolio Holdings Detail for ISIN IE00BMZ17X30
Stock Name / Fund iShares MSCI World SRI UCITS ETF USD Hedged (Dist)
Issuer Blackrock
Entity holding fund iShares IV Public Limited Company
Entity Type
Entity LEI 549300ZP07LMR36K1T02
ETF Ticker SUWU(USD) Euronext Amsterdam

Holdings detail for ALNY

Stock Name	Alnylam Pharmaceuticals Inc
Ticker	ALNY(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US02043Q1076
LEI	529900S3ZI14OWRJII50

Show aggregate ALNY holdings

News associated with ALNY

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $500.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by Royal Bank Of Canada from $435.00 to $500.00 in a report issued on Friday morning,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. ALNY has been the topic of several other reports. The Goldman Sachs Group boosted their price […] - 2025-09-22 02:32:43
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $520.00 Price Target at Bank of America: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective raised by Bank of America from $453.00 to $520.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also weighed in on ALNY. Oppenheimer upgraded shares […] - 2025-09-18 04:26:54
The Goldman Sachs Group Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by The Goldman Sachs Group from $504.00 to $566.00 in a report published on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also commented on the stock. Chardan Capital lifted […] - 2025-09-17 03:14:44
Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $421.28: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-seven analysts that are covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and twenty-three have issued a buy recommendation on the company. The average 1 year target price […] - 2025-09-15 02:47:58
Alnylam Announces Pricing Of Upsized Offering Of $575 Mln Convertible Senior Notes Due 2028: (RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced the pricing of its private offering of $575 million aggregate principal amount of 0.00% convertible senior notes due 2028. The size of the offering was increased from the previously announced offering of $500 million aggre - 2025-09-10 00:33:28
Alnylam Pharma Commences Private Offering Of $500 Mln Of Convertible Senior Notes Due 2028: (RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced that it has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028. In connection with this offering, Alnylam expects to grant the initial purchasers of the notes an op - 2025-09-09 00:30:30
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win: Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study. - 2025-09-01 11:50:00
Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11
Dennis A. Ausiello Sells 31,448 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Dennis A. Ausiello sold 31,448 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the sale, the director directly owned 911 shares in […] - 2025-08-18 05:14:55
LPL Financial LLC Buys 2,107 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): LPL Financial LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 11.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,679 shares of the biopharmaceutical company’s stock after acquiring an additional 2,107 shares during the period. LPL Financial LLC’s holdings […] - 2025-08-13 05:04:56
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Cetera Investment Advisers Has $2.17 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Cetera Investment Advisers raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 68.1% during the first quarter, Holdings Channel reports. The firm owned 8,017 shares of the biopharmaceutical company’s stock after purchasing an additional 3,247 shares during the period. Cetera Investment Advisers’ holdings in Alnylam Pharmaceuticals were worth $2,165,000 at the end […] - 2025-08-08 04:44:59
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at Oppenheimer: Oppenheimer upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a market perform rating to an outperform rating in a research report sent to investors on Monday, Marketbeat.com reports. The brokerage currently has $490.00 target price on the biopharmaceutical company’s stock. ALNY has been the subject of several other reports. Barclays lifted their price […] - 2025-08-07 02:54:47
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by Wolfe Research to Peer Perform Rating: Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by equities research analysts at Wolfe Research from an “underperform” rating to a “peer perform” rating in a research report issued on Monday, Marketbeat reports. A number of other brokerages have also recently issued reports on ALNY. Canaccord Genuity Group lifted their price target on shares […] - 2025-08-06 03:02:54
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $400.00 at Chardan Capital: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by Chardan Capital from $325.00 to $400.00 in a research report report published on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also issued reports on ALNY. Needham & Company LLC raised their […] - 2025-08-04 02:48:47
Needham & Company LLC Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $478.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target hoisted by Needham & Company LLC from $377.00 to $478.00 in a research report report published on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock. A number of other research analysts also recently commented on the […] - 2025-08-03 05:28:56
Noteworthy ETF Outflows: XBI, MRNA, ALNY, EXEL: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $225.3 million dollar outflow -- that's a 4.6% decrease week over week - 2025-07-30 11:49:03
Y Intercept Hong Kong Ltd Has $1 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Y Intercept Hong Kong Ltd lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 17.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,720 shares of the biopharmaceutical company’s stock after selling 796 shares during the period. […] - 2025-07-25 06:12:53
Victory Capital Management Inc. Cuts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Victory Capital Management Inc. lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,649 shares of the biopharmaceutical company’s stock after selling 2,148 shares during the period. Victory Capital […] - 2025-07-25 05:14:50
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the twenty-six research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twenty-two have assigned a buy recommendation to the […] - 2025-07-24 06:26:55
Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Truist Financial: Truist Financial initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report sent to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $385.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts also recently issued reports on ALNY. Jefferies Financial […] - 2025-07-22 03:14:59
Nisa Investment Advisors LLC Cuts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Nisa Investment Advisors LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 38.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,155 shares of the biopharmaceutical company’s stock after selling 5,162 shares during […] - 2025-07-14 05:54:56
Crossmark Global Holdings Inc. Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Crossmark Global Holdings Inc. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,018 shares of the biopharmaceutical company’s stock, valued at approximately $275,000. Other hedge funds have also modified their holdings of the […] - 2025-07-14 05:14:48
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Vontobel Holding Ltd.: Vontobel Holding Ltd. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,691 shares of the biopharmaceutical company’s stock after selling 113 shares during the […] - 2025-07-08 04:40:51
Mirae Asset Global Investments Co. Ltd. Sells 2,596 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Mirae Asset Global Investments Co. Ltd. reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 28.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,534 shares of the biopharmaceutical company’s stock after selling 2,596 shares during the […] - 2025-07-04 04:52:27
Wells Fargo & Company Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $333.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price target lifted by research analysts at Wells Fargo & Company from $287.00 to $333.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside […] - 2025-07-02 03:05:01
Diversified Trust Co Sells 999 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Diversified Trust Co cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 40.3% in the first quarter, Holdings Channel reports. The institutional investor owned 1,482 shares of the biopharmaceutical company’s stock after selling 999 shares during the period. Diversified Trust Co’s holdings in Alnylam Pharmaceuticals were worth $400,000 as of […] - 2025-07-01 07:10:56
Sequoia Financial Advisors LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Sequoia Financial Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 3.0% in the first quarter, HoldingsChannel reports. The fund owned 3,395 shares of the biopharmaceutical company’s stock after acquiring an additional 99 shares during the period. Sequoia Financial Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $917,000 […] - 2025-07-01 05:22:50
Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High Following Analyst Upgrade: Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) hit a new 52-week high on Monday after Wells Fargo & Company raised their price target on the stock from $287.00 to $333.00. Wells Fargo & Company currently has an equal weight rating on the stock. Alnylam Pharmaceuticals traded as high as $327.05 and last […] - 2025-07-01 02:27:01
Kentucky Retirement Systems Buys New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Kentucky Retirement Systems bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,794 shares of the biopharmaceutical company’s stock, valued at approximately $2,375,000. Several other institutional investors and […] - 2025-06-24 06:20:52

iShares MSCI World SRI UCITS ETF USD Hedged (Dist) ALNY holdings

Date	Number of ALNY Shares Held	Base Market Value of ALNY Shares	Local Market Value of ALNY Shares	Change in ALNY Shares Held	Change in ALNY Base Value	Current Price per ALNY Share Held	Previous Price per ALNY Share Held
2025-11-27 (Thursday)	65,747	USD 29,265,305	USD 29,265,305	0	USD 0	USD 445.12	USD 445.12
2025-11-26 (Wednesday)	65,747	USD 29,265,305	USD 29,265,305	0	USD 1,007,244	USD 445.12	USD 429.8
2025-11-25 (Tuesday)	65,747	USD 28,258,061	USD 28,258,061	0	USD -291,259	USD 429.8	USD 434.23
2025-11-24 (Monday)	65,747	USD 28,549,320	USD 28,549,320	-216	USD -235,614	USD 434.23	USD 436.38
2025-11-21 (Friday)	65,963	USD 28,784,934	USD 28,784,934	0	USD -620,712	USD 436.38	USD 445.79
2025-11-20 (Thursday)	65,963	USD 29,405,646	USD 29,405,646	0	USD -987,466	USD 445.79	USD 460.76
2025-11-19 (Wednesday)	65,963	USD 30,393,112	USD 30,393,112	-146	USD -169,079	USD 460.76	USD 462.3
2025-11-18 (Tuesday)	66,109	USD 30,562,191	USD 30,562,191	-365	USD -51,745	USD 462.3	USD 460.54
2025-11-17 (Monday)	66,474	USD 30,613,936	USD 30,613,936	0	USD 756,474	USD 460.54	USD 449.16
2025-11-14 (Friday)	66,474	USD 29,857,462	USD 29,857,462	0	USD -319,740	USD 449.16	USD 453.97
2025-11-13 (Thursday)	66,474	USD 30,177,202	USD 30,177,202	-292	USD -50,437	USD 453.97	USD 452.74
2025-11-12 (Wednesday)	66,766	USD 30,227,639	USD 30,227,639	-146	USD -13,239	USD 452.74	USD 451.95
2025-11-11 (Tuesday)	66,912	USD 30,240,878	USD 30,240,878	0	USD 685,848	USD 451.95	USD 441.7
2025-11-10 (Monday)	66,912	USD 29,555,030	USD 29,555,030	-292	USD -196,181	USD 441.7	USD 442.7

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ALNY by Blackrock for IE00BMZ17X30

Show aggregate share trades of ALNY

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-24 SELL -216 444.670 420.345 422.778 USD -91,320 396.57 Loss of -5,661 on sale
2025-11-19 SELL -146 465.320 456.900 457.742 USD -66,830 394.89 Loss of -9,177 on sale
2025-11-18 SELL -365 469.110 456.270 457.554 USD -167,007 394.14 Loss of -23,147 on sale
2025-11-13 SELL -292 456.140 447.155 448.054 USD -130,832 392.05 Loss of -16,352 on sale
2025-11-12 SELL -146 459.270 447.130 448.344 USD -65,458 391.35 Loss of -8,321 on sale
2025-11-10 SELL -292 449.680 440.930 441.805 USD -129,007 390.03 Loss of -15,119 on sale
2025-11-07 SELL -656 443.587 430.835 432.110 USD -283,464 389.39 Loss of -28,023 on sale
2025-11-06 BUY 142 445.490 429.000 430.649 USD 61,152 388.77
2025-11-05 BUY 219 438.530 417.000 419.153 USD 91,795 388.20
2025-10-31 SELL -146 459.570 441.220 443.055 USD -64,686 386.29 Loss of -8,287 on sale
2025-10-30 SELL -73 471.980 436.512 440.059 USD -32,124 385.47 Loss of -3,985 on sale
2025-10-24 SELL -803 463.430 469.290 468.704 USD -376,369 380.57 Loss of -70,768 on sale
2025-10-22 SELL -365 464.900 480.530 478.967 USD -174,823 378.21 Loss of -36,776 on sale
2025-10-15 SELL -365 470.270 485.280 483.779 USD -176,579 370.53 Loss of -41,337 on sale
2025-10-01 SELL -803 460.650 467.420 466.743 USD -374,795 361.60 Loss of -84,432 on sale
2025-09-26 SELL -288 446.400 453.050 452.385 USD -130,287 356.95 Loss of -27,486 on sale
2025-09-24 SELL -1,440 458.370 462.690 462.258 USD -665,652 353.42 Loss of -156,729 on sale
2025-09-17 SELL -852 451.730 463.880 462.665 USD -394,191 349.70 Loss of -96,246 on sale
2025-09-11 BUY 144 468.580 474.340 473.764 USD 68,222 342.77
2025-07-25 BUY 144 328.810 331.500 331.231 USD 47,697 316.18
2025-07-21 BUY 360 320.520 328.700 327.882 USD 118,038 315.18
2025-07-17 BUY 1,033 324.690 329.870 329.352 USD 340,221 314.73
2025-07-11 BUY 151 314.940 321.120 320.502 USD 48,396 314.54
2025-07-07 SELL -1,224 324.130 328.240 327.829 USD -401,263 313.46 Loss of -17,592 on sale
2025-07-03 BUY 72 331.910 333.700 333.521 USD 24,014 311.85
2025-07-02 BUY 73 329.770 330.000 329.977 USD 24,088 311.04
2025-06-30 BUY 72 326.090 327.210 327.098 USD 23,551 309.73
2025-06-26 BUY 144 318.250 325.000 324.325 USD 46,703 308.53
2025-06-20 SELL -1,800 309.700 314.500 314.020 USD -565,236 305.99 Loss of -14,458 on sale
2025-06-18 BUY 72 312.320 317.540 317.018 USD 22,825 304.93
2025-06-16 BUY 72 308.780 309.630 309.545 USD 22,287 304.17
2025-06-06 BUY 72 300.830 310.220 309.281 USD 22,268 305.79
2025-06-04 BUY 144 305.310 308.930 308.568 USD 44,434 304.93
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-24	SELL	-216	444.670	420.345	422.778	USD -91,320	396.57 Loss of -5,661 on sale
2025-11-19	SELL	-146	465.320	456.900	457.742	USD -66,830	394.89 Loss of -9,177 on sale
2025-11-18	SELL	-365	469.110	456.270	457.554	USD -167,007	394.14 Loss of -23,147 on sale
2025-11-13	SELL	-292	456.140	447.155	448.054	USD -130,832	392.05 Loss of -16,352 on sale
2025-11-12	SELL	-146	459.270	447.130	448.344	USD -65,458	391.35 Loss of -8,321 on sale
2025-11-10	SELL	-292	449.680	440.930	441.805	USD -129,007	390.03 Loss of -15,119 on sale
2025-11-07	SELL	-656	443.587	430.835	432.110	USD -283,464	389.39 Loss of -28,023 on sale
2025-11-06	BUY	142	445.490	429.000	430.649	USD 61,152	388.77
2025-11-05	BUY	219	438.530	417.000	419.153	USD 91,795	388.20
2025-10-31	SELL	-146	459.570	441.220	443.055	USD -64,686	386.29 Loss of -8,287 on sale
2025-10-30	SELL	-73	471.980	436.512	440.059	USD -32,124	385.47 Loss of -3,985 on sale
2025-10-24	SELL	-803	463.430	469.290	468.704	USD -376,369	380.57 Loss of -70,768 on sale
2025-10-22	SELL	-365	464.900	480.530	478.967	USD -174,823	378.21 Loss of -36,776 on sale
2025-10-15	SELL	-365	470.270	485.280	483.779	USD -176,579	370.53 Loss of -41,337 on sale
2025-10-01	SELL	-803	460.650	467.420	466.743	USD -374,795	361.60 Loss of -84,432 on sale
2025-09-26	SELL	-288	446.400	453.050	452.385	USD -130,287	356.95 Loss of -27,486 on sale
2025-09-24	SELL	-1,440	458.370	462.690	462.258	USD -665,652	353.42 Loss of -156,729 on sale
2025-09-17	SELL	-852	451.730	463.880	462.665	USD -394,191	349.70 Loss of -96,246 on sale
2025-09-11	BUY	144	468.580	474.340	473.764	USD 68,222	342.77
2025-07-25	BUY	144	328.810	331.500	331.231	USD 47,697	316.18
2025-07-21	BUY	360	320.520	328.700	327.882	USD 118,038	315.18
2025-07-17	BUY	1,033	324.690	329.870	329.352	USD 340,221	314.73
2025-07-11	BUY	151	314.940	321.120	320.502	USD 48,396	314.54
2025-07-07	SELL	-1,224	324.130	328.240	327.829	USD -401,263	313.46 Loss of -17,592 on sale
2025-07-03	BUY	72	331.910	333.700	333.521	USD 24,014	311.85
2025-07-02	BUY	73	329.770	330.000	329.977	USD 24,088	311.04
2025-06-30	BUY	72	326.090	327.210	327.098	USD 23,551	309.73
2025-06-26	BUY	144	318.250	325.000	324.325	USD 46,703	308.53
2025-06-20	SELL	-1,800	309.700	314.500	314.020	USD -565,236	305.99 Loss of -14,458 on sale
2025-06-18	BUY	72	312.320	317.540	317.018	USD 22,825	304.93
2025-06-16	BUY	72	308.780	309.630	309.545	USD 22,287	304.17
2025-06-06	BUY	72	300.830	310.220	309.281	USD 22,268	305.79
2025-06-04	BUY	144	305.310	308.930	308.568	USD 44,434	304.93

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ALNY

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	216,727	3,259	396,243	54.7%
2025-09-18	172,875	397	386,432	44.7%
2025-09-17	246,547	167	472,292	52.2%
2025-09-16	88,846	60	226,336	39.3%
2025-09-15	148,258	13,572	435,689	34.0%
2025-09-12	134,122	300	244,968	54.8%
2025-09-11	219,868	7,820	411,702	53.4%
2025-09-10	543,326	7,595	916,898	59.3%
2025-09-09	705,540	33,731	1,550,899	45.5%
2025-09-08	175,158	440	388,715	45.1%
2025-09-05	127,116	335	311,252	40.8%
2025-09-04	110,930	2,555	236,568	46.9%
2025-09-03	182,386	8,982	562,921	32.4%
2025-09-02	132,770	14,416	358,476	37.0%
2025-08-29	93,216	2,181	276,594	33.7%
2025-08-28	60,182	1,254	226,865	26.5%
2025-08-27	277,667	1,084	440,577	63.0%
2025-08-26	243,404	919	447,421	54.4%
2025-08-25	156,551	15,662	374,276	41.8%
2025-08-22	228,596	1,309	408,152	56.0%
2025-08-21	123,996	2,862	248,300	49.9%
2025-08-20	149,638	13,723	316,983	47.2%
2025-08-19	144,320	1,143	308,399	46.8%
2025-08-18	371,318	34,264	525,786	70.6%
2025-08-15	104,018	13,245	265,620	39.2%
2025-08-14	133,272	4,443	505,528	26.4%
2025-08-13	183,271	1,390	1,017,623	18.0%
2025-08-12	173,045	4,046	693,018	25.0%
2025-08-11	239,199	7,600	451,248	53.0%
2025-08-08	168,755	3,199	466,744	36.2%
2025-08-07	308,810	4,452	527,399	58.6%
2025-08-06	202,151	12,590	548,349	36.9%
2025-08-05	256,295	13,237	826,283	31.0%
2025-08-04	411,114	36,303	729,949	56.3%
2025-08-01	350,060	60,108	764,943	45.8%
2025-07-31	829,191	6,023	1,541,015	53.8%
2025-07-30	533,885	14,703	942,788	56.6%
2025-07-29	164,268	55	384,537	42.7%
2025-07-28	150,240	69	571,965	26.3%
2025-07-25	90,782	429	298,801	30.4%
2025-07-24	132,001	11,546	286,155	46.1%
2025-07-23	184,149	63	312,340	59.0%
2025-07-22	134,761	7,553	524,612	25.7%
2025-07-21	113,303	101	243,119	46.6%
2025-07-18	84,117	9	196,317	42.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.